Sonoma Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Sonoma Pharmaceuticals, Inc.'s yearly results (2023–2026), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 629% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 87% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 2 of the last 3 years; profit grew in 3 of 3. Steadier than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-23.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 60% of Healthcare companies in United States.
Cash Locked Ratio
$37For every $100 of sales, $37 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $64 tied up three years earlier.
More money tied up than 77% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 3/3Sales grew in 2 of the last 3 years; profit grew in 3 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$32Sales grew 47% in 3 years; of every extra $100 of sales, $32 became extra profit.
Higher than 58% of Healthcare companies in United States.
Asset Productivity Ratio
+47% / -14%In 3 years sales changed by +47% while total assets changed by -14%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-17.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 52% of Healthcare companies in United States.
Cash Cushion Ratio
+28%Cash, after subtracting all debt, equals 28% of its market value (net cash).
Higher than 67% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Sonoma Pharmaceuticals, Inc. made a loss over the last year. Sonoma Pharmaceuticals, Inc. owes $0.64 for every $1 it owns. Sonoma Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Mar 2026.
P/E ratio
LossSonoma Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.84The share price is 0.84 times Sonoma Pharmaceuticals, Inc.'s book value per share, lower than 83% of Healthcare companies in United States.
Market cap
$6 MThe total market value of all of Sonoma Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), smaller than 92% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$7 MWhat Sonoma Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.38Net worth divided by the number of shares. The share price of $1.15 is 0.8 times this, which is the P/B above.
Return on equity (ROE)
-42.5%Sonoma Pharmaceuticals, Inc. lost 42.5% of its shareholders' money over the last year, higher than 53% of Healthcare companies in United States.
Owes vs Owns
0.64×Sonoma Pharmaceuticals, Inc. owes $0.64 for every $1 it owns (moderate), higher than 67% of Healthcare companies in United States.
Dividend yield
NoneSonoma Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+37%Revenue rose 37% in the year to Mar 2026, and grew 14% a year on average over 3 years.
Profit growth
LossSonoma Pharmaceuticals, Inc. made a loss in each of the last two years.
Profit margin
-16.3%Sonoma Pharmaceuticals, Inc. lost $16 for every $100 of revenue.
Cash vs debt
Net cashSonoma Pharmaceuticals, Inc. held $2 M more cash than debt (net cash) at Mar 2026.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Sonoma Pharmaceuticals, Inc.: $6 M ÷ $7 M (30 Jun 2026) = 0.8.
What is Sonoma Pharmaceuticals, Inc.'s return on equity?
Sonoma Pharmaceuticals, Inc. lost 42.5% of its shareholders' money over the last year, higher than 53% of Healthcare companies in United States.
How much does Sonoma Pharmaceuticals, Inc. owe compared with what it owns?
Sonoma Pharmaceuticals, Inc. owes $0.64 for every $1 it owns (moderate), higher than 67% of Healthcare companies in United States.
Does Sonoma Pharmaceuticals, Inc. pay a dividend?
No. Sonoma Pharmaceuticals, Inc. does not currently pay a dividend.
Is Sonoma Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 37% in the year to Mar 2026, and grew 14% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.